Joshua B. Cohen - 16 Nov 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Justin Klee, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
16 Nov 2023
Net transactions value
+$100,000
Form type
4
Filing time
20 Nov 2023, 20:20:39 UTC
Previous filing
20 Mar 2023
Next filing
11 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $100,000 +63,694 +2.2% $1.57* 2,906,311 16 Nov 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Options Exercise $0 -63,694 -64% $0.000000 36,306 16 Nov 2023 Common Stock 63,694 $1.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25,012 shares subject to such option vested and became exercisable on February 26, 2021, with the remaining shares vesting in monthly installments of 2,083 shares thereafter.

Remarks:

Exhibit List: Exhibit 24. This Power of Attorney was inadvertently omitted from the Form 3 filed on January 6, 2022.